6533b854fe1ef96bd12ae823

RESEARCH PRODUCT

Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

A.s. JungMarc PeetersCornelis J. A. PuntEmily ChanAndrés CervantesEric Van CutsemAndrew StricklandFlorian LordickLaslo RomanMichel DucreuxScott D. PattersonAlberto SobreroHua YuYevhen HotkoTimothy J. PriceGregory C. WilsonThierry AndréTudor CiuleanuKelly S. OlinerRoger Sidhu

subject

Neuroblastoma RAS viral oncogene homologOncologyCancer Researchmedicine.medical_specialtySecond line treatmentbusiness.industryColorectal cancerBioinformaticsmedicine.diseasemedicine.disease_causeOncologyInternal medicineFOLFIRIMedicinePanitumumabKRASbusinessneoplasmsmedicine.drug

description

3568 Background: Previously, extended RAS analysis from this study showed a trend toward improvements in HR on OS and PFS with pmab + FOLFIRI vs FOLFIRI in WT RAS group vs WT KRAS exon 2 group. Her...

https://doi.org/10.1200/jco.2014.32.15_suppl.3568